Advances in pharmacotherapy for ulcerative colitis: a focus on JAK1 inhibitors

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389:1756–1770.
   PubMed Web of Science ®Google Scholar
• Ordás I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet. 2012;380:1606–1619.
   PubMed Web of Science ®Google Scholar
• Jairath V, Feagan BG. Global burden of inflammatory bowel disease. Lancet Gastroenterol Hepatol. 2020;5:2–3.
   PubMed Web of Science ®Google Scholar
• Alatab S, Sepanlou SG, Ikuta K, et al. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.
   PubMed Web of Science ®Google Scholar
• Neurath MF. Cytokines in inflammatory bowel disease. Nat Rev Immunol. 2014;14:329–342.
   PubMed Web of Science ®Google Scholar
• EMA. Zeposia [Internet]. European Medicines Agency. 2020 [cited 2023 Jan 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/zeposia
   Google Scholar
• U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Zeposia® (ozanimod), An oral treatment for adults with moderately to severely active ulcerative colitis1 [Internet]. [cited 2023 Jan 12]. Available from: https://news.bms.com/news/details/2021/U.S.-Food-and-Drug-Administration-Approves-Bristol-Myers-Squibbs-Zeposia-ozanimod-an-Oral-Treatment-for-Adults-with-Moderately-to-Severely-Active-Ulcerative-Colitis1/default.aspx
   Google Scholar
• Gordon JP, McEwan PC, Maguire A, et al. Characterizing unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015;27:804–812.
   PubMed Web of Science ®Google Scholar
• McLornan DP, Pope JE, Gotlib J, et al. Current and future status of JAK inhibitors. Lancet. 2021;398:803–816.
   PubMed Web of Science ®Google Scholar
• Casellas F, González-Lama Y, Ginard Vicens D, et al. Adherence improvement in patients with ulcerative colitis: a multidisciplinary consensus document. Rev Esp Enferm Dig. 2022;114:156–165.
   PubMedGoogle Scholar
• Danese S, Allez M, van Bodegraven AA, et al. Unmet medical needs in ulcerative colitis: an expert group consensus. DDI. 2019;37:266–283.
   Google Scholar
• Olivera P, Danese S, Peyrin-Biroulet L. Next generation of small molecules in inflammatory bowel disease. Gut. 2017;66:199–209.
   PubMed Web of Science ®Google Scholar
• Padda IS, Bhatt R, Parmar M Tofacitinib [Internet]. PubMed. StatPearls Publishing; 2022 [cited 2022 Jan 1]. Available from: https://pubmed.ncbi.nlm.nih.gov/34283514/
   Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Commissioner O of the. FDA approves new treatment for moderately to severely active ulcerative colitis [Internet]. FDA. FDA; 2020 [cited 2023 Jan 12]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-moderately-severely-active-ulcerative-colitis
   Google Scholar
• XELJANZ® (tofacitinib citrate) receives marketing authorization in the European Union for moderately to severely active ulcerative colitis | Pfizer [Internet]. [cited 2023 Jan 12]. Pfizer [Internet] https://www.pfizer.com/news/press-release/press-release-detail/xeljanz_tofacitinib_citrate_receives_marketing_authorization_in_the_european_union_for_moderately_to_severely_active_ulcerative_colitis-0
   Google Scholar
• EMA. Xeljanz [Internet]. European Medicines Agency. 2018 [cited 2023 Jan 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz
   Google Scholar
• Danese S, Grisham M, Hodge J, et al. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines. Am J Physiol Gastrointest Liver Physiol. 2016;310:G155–162.
   PubMed Web of Science ®Google Scholar
• Lefevre PLC, Vande Casteele N. Clinical pharmacology of janus kinase inhibitors in inflammatory bowel disease. J Crohn’s Colitis. 2020;14:S725–736.
   Google Scholar
• McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21:183.
   PubMed Web of Science ®Google Scholar
• JAK–STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects | SpringerLink [Internet]. [cited 2023 Jan 18]. [Internet]: https://link.springer.com/article/10.1007/s40265-017-0701-9
   Google Scholar
• EMA. Increased risk of blood clots in lungs and death with higher dose Xeljanz (tofacitinib) for rheumatoid arthritis [Internet]. European Medicines Agency. 2019 [cited 2023 Jan 18]. Available from: https://www.ema.europa.eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis
   Google Scholar
• Research C for DE and. Safety trial finds risk of blood clots in the lungs and death with higher dose of tofacitinib (Xeljanz, Xeljanz XR) in rheumatoid arthritis patients; FDA to investigate. FDA [Internet]. 2019 [cited 2023 Jan 18]; Available from: https://www.fda.gov/drugs/drug-safety-and-availability/safety-trial-finds-risk-blood-clots-lungs-and-death-higher-dose-tofacitinib-xeljanz-xeljanz-xr
   Google Scholar
• Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316–326.
   PubMed Web of Science ®Google Scholar
• NV G. Jyseleca® approved in Japan for ulcerative colitis [Internet]. GlobeNewswire News Room. 2022 [cited 2022 Jan 1]. Available from: https://www.globenewswire.com/en/news-release/2022/03/28/2410628/0/en/Jyseleca-approved-in-Japan-for-ulcerative-colitis.html
   Google Scholar
• EMA. Jyseleca - European medicines agency [internet]. European Medicines Agency. 2020 [cited 2022 Jan 1]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/jyseleca
   Google Scholar
• D’Amico F, Magro F, Peyrin-Biroulet L, et al. Positioning filgotinib in the treatment algorithm of moderate to severe ulcerative colitis. J Crohn’s Colitis. 2021;16:835–844.
   Google Scholar
• Genovese MC, Kalunian K, Gottenberg J-E, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy. JAMA. 2019;322:315.
   PubMed Web of Science ®Google Scholar
• Hanzel J, Hulshoff MS, Grootjans J, et al. Emerging therapies for ulcerative colitis. Expert Rev Clin Immunol. 2022;18:513–524.
   PubMed Web of Science ®Google Scholar
• RINVOQ® (Upadacitinib) Receives its sixth U.S. FDA approval | AbbVie news center [Internet]. news.abbvie.com. 2022 [cited 2022 Jan 1]. Available from: https://news.abbvie.com/news/press-releases/rinvoq-upadacitinib-receives-its-sixth-us-fda-approval.htm
   Google Scholar
• EMA. Rinvoq - European medicines agency [internet]. European Medicines Agency. 2019. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq
   Google Scholar
• Reistone Biopharma Company Limited. A phase 3 study to evaluate the efficacy and long-term safety of SHR0302 therapy in subjects with moderately to severely active ulcerative colitis [Internet]. clinicaltrials.gov. 2022 [cited 2022 Jan 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT05181137?term=SHR0302&draw=3&rank=19
   Google Scholar
• Danese S, Argollo M, Le Berre C, et al. JAK selectivity for inflammatory bowel disease treatment: does it clinically matter? Gut. 2019;68:1893–1899.
   PubMed Web of Science ®Google Scholar
• Babon JJ, Lucet IS, Murphy JM, et al. The molecular regulation of janus kinase (JAK) activation. Biochem J. 2014;462:1–13.
   PubMed Web of Science ®Google Scholar
• Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021;6:402.
   PubMed Web of Science ®Google Scholar
• Owen KL, Brockwell NK, Parker BS. JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel). 2019;11:2002.
   PubMed Web of Science ®Google Scholar
• Salas A, Hernandez-Rocha C, Duijvestein M, et al. JAK–STAT pathway targeting for the treatment of inflammatory bowel disease. Nat Rev Gastroenterol Hepatol. 2020;17:323–337.
   PubMed Web of Science ®Google Scholar
• Harris C, Cummings JRF. JAK1 inhibition and inflammatory bowel disease. Rheumatology (Oxford). 2021;60:ii45–51.
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bingham CO, Cappelli LC, et al. Postapproval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-year results from a United States-based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3:173–184.
   PubMedGoogle Scholar
• Burmester GR, Nash P, Sands BE, et al. Adverse events of special interest in clinical trials of rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and psoriasis with 37 066 patient-years of tofacitinib exposure. RMD Open. 2021;7:e001595.
   PubMed Web of Science ®Google Scholar
• van der Heijde D, Baraliakos X, Gensler LS, et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet (London, England). 2018;392:2378–2387.
   PubMedGoogle Scholar
• Mease P, Coates LC, Helliwell PS, et al. Efficacy and safety of filgotinib, a selective janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet. 2018;392:2367–2377.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Westhovens RR, Winthrop KL, et al. Safety and efficacy of filgotinib: up to 4-year results from an open-label extension study of phase ii rheumatoid arthritis programs. J Rheumatol. 2021;48:1230–1238.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389:266–275.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Danese S, Loftus EV, et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial. Lancet. 2021;397:2372–2384.
   PubMed Web of Science ®Google Scholar
• Hibi T, Motoya S, Hisamatsu T, et al. Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial. Intest Res. 2022;21:110–125.
   PubMedGoogle Scholar
• Namour F, Anderson K, Nelson C, et al. Filgotinib: a clinical pharmacology review. Clin Pharmacokinet. 2022;61:819–832.
   PubMed Web of Science ®Google Scholar
• Galapagos NV, Gilead Sciences. A long-term extension study to evaluate the safety of filgotinib in subjects with ulcerative colitis [Internet]. clinicaltrials.gov. 2021 [cited 2022 Jan 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT02914535
   Google Scholar
• Geboes K. A reproducible grading scale for histological assessment of inflammation in ulcerative colitis. Gut. 2000;47:404–409.
   PubMed Web of Science ®Google Scholar
• Westhovens R, Taylor PC, Alten R, et al. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (mtx) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1). Ann Rheumatic Dis. 2017;76:998–1008.
   PubMed Web of Science ®Google Scholar
• Kavanaugh A, Kremer J, Ponce L, et al. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2). Ann Rheumatic Dis. 2017;76:1009–1019.
   PubMed Web of Science ®Google Scholar
• Galapagos NV, A randomized double-blind, placebo-controlled phase 2 study to evaluate the testicular safety of filgotinib in adult males with moderately to severely active inflammatory bowel disease [Internet]. 2022 [cited 2023 Jan 18]. Report No.: study/NCT03201445. [Internet]: https://clinicaltrials.gov/ct2/show/study/NCT03201445
   Google Scholar
• Galapagos NV, A randomized double-blind, placebo-controlled phase 2 study to evaluate the effect of filgotinib on semen parameters in adult males with active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis or non-radiographic axial spondyloarthritis [Internet]. 2022 [cited 2023 Jan 18]. Report No.: NCT03926195. [Internet]: https://clinicaltrials.gov/ct2/show/NCT03926195
   Google Scholar
• Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies [Internet]. [cited 2023 Feb 27]. Available from: https://www.glpg.com/press-release/3687/galapagos-receives-positive-chmp-opinion-for-jyseleca-european-label-update-based-on-testicular-function-safety-data-from-manta-ray-studies
   Google Scholar
• Mohamed ME, Klünder B, Othman AA. Clinical pharmacokinetics of upadacitinib: review of data relevant to the rheumatoid arthritis indication. Clin Pharmacokinet. 2019;59:531–544.
   Google Scholar
• Danese S, Vermeire S, Zhou W, et al. Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials. Lancet. 2022;399:2113–2128.
   PubMed Web of Science ®Google Scholar
• Vermeire S European Crohn´s and colitis organisation - ECCO - DOP38 upadacitinib therapy reduces ulcerative colitis symptoms as early as Day 1 [Internet]. [cited 2022 Jan 1]. [Internet] https://www.ecco-ibd.eu/publications/congress-abstracts/item/dop38-upadacitinib-therapy-reduces-ulcerative-colitis-symptoms-as-early-as-day-1.html
   Google Scholar
• Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with crohn’s disease. Gastroenterology. 2020;158:2123–2138.e8.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Thaçi D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145:877–884.
   PubMed Web of Science ®Google Scholar
• Chen B, Zhong J, Li X, et al. Efficacy and safety of ivarmacitinib in patients with moderate-to-severe, active, ulcerative colitis: a phase II study. Gastroenterology. 2022;163:1555–1568.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Zhang L, Ding Y, et al. Efficacy and safety of SHR0302, a highly selective janus kinase 1 inhibitor, in patients with moderate to severe atopic dermatitis: a phase ii randomized clinical trial. Am J Clin Dermatol. 2021;22:877–889.
   PubMed Web of Science ®Google Scholar
• A multicenter, randomized, placebo-controlled, double-blind phase 2 study of SHR0302 versus placebo in Chinese subjects with moderate to severe active rheumatoid arthritis (RA) [Internet]. ACR Meeting Abstracts. [cited 2023 Jan 12]. Available from: https://acrabstracts.org/abstract/a-multicenter-randomized-placebo-controlled-double-blind-phase-2-study-of-shr0302-versus-placebo-in-chinese-subjects-with-moderate-to-severe-active-rheumatoid-arthritis-ra/
   Google Scholar
• Jiangsu HengRui Medicine Co., Ltd. Randomized, double-blind, placebo-controlled, multicenter, phase ii study to assess the safety and efficacy of SHR0302 in patients with moderate to severe active rheumatoid arthritis [Internet]. clinicaltrials.gov; 2021 [cited 2023 Jan 10]. Report No.: study/NCT03254966. [Internet]. clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/study/NCT03254966
   Google Scholar
• D’Amico F, Peyrin-Biroulet L, Danese S. Is selectivity the JAKpot winner for inflammatory bowel disease treatment? Gastroenterology. 2022;163:1482–1484.
   PubMedGoogle Scholar
• EMA. Meeting highlights from the pharmacovigilance risk assessment committee (PRAC) 24 - 27 October 2022 European medicines agency [Internet]. European Medicines Agency. 2022 [cited 2023 Jan 1]. Available from: https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-24-27-october-2022
   Google Scholar
• Kristensen LE, Danese S, Yndestad A, et al. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Annals of the Rheumatic Diseases [Internet]. 2023 [cited 2023 Mar 26]; Available from: https://ard.bmj.com/content/early/2023/03/16/ard-2022-223715
   Google Scholar
• Lasa JS, Olivera PA, Danese S, et al. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2022;7:161–170.
   PubMed Web of Science ®Google Scholar
• Burr NE, Gracie DJ, Black CJ, et al. Efficacy of biological therapies and small molecules in moderate to severe ulcerative colitis: systematic review and network meta-analysis. Gut. 2021;71: gutjnl-2021-326390.
   PubMedGoogle Scholar
• D’Amico F, Peyrin-Biroulet L, Danese S. Tofacitinib for acute severe colitis: when the going gets tough, the tough get going. J Crohn’s Colitis. 2020;14:883–885.
   Google Scholar
• Danese S, Solitano V, Jairath V, et al. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut. 2022;71:2380–2387.
   PubMedGoogle Scholar
• Oncostellae SL A phase Ib/IIa, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis [Internet]. clinicaltrials.gov; 2023 [cited 2023 Mar 28]. Report No.: NCT04353791. [Internet]. clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT04353791
   Google Scholar
• Bristol-Myers Squibb. A phase 2 randomized, double-blind, placebo-controlled study of the safety and efficacy of BMS-986165 in subjects with moderate to severe ulcerative colitis [Internet]. clinicaltrials.gov;2023 [cited 2023 Mar 28]. Report No.: NCT03934216. [Internet]. clinicaltrials.gov: https://clinicaltrials.gov/ct2/show/NCT03934216
   Google Scholar
• Sandborn WJ, Danese S, Leszczyszyn J, et al. Oral Ritlecitinib And Brepocitinib For Moderate-to-Severe Ulcerative Colitis: Results From A Randomized, Phase 2b study. Clinical Gastroenterology and Hepatology [Internet]. 2023 [cited 2023 Mar 31]. Available from: https://www.cghjournal.org/article/S1542-35652300007-1/fulltext
   Google Scholar